This week’s funding highlight was Kardium’s impressive $250m round to support its pulsed field ablation technology – yet there were many other updates that shouldn’t fly under your radar! Whether they are targeting heart rhythm disorders, organ prolapse, or unlocking new drug targets through AI, the MedTechs featured below are making meaningful progress in patient care.
Kardium raises $250m to support PFA system launch
Kardium has raised $250 million to support the commercial launch of its Globe pulsed field ablation (PFA) system for treating atrial fibrillation (AFib). The latest fund raise brings the company’s total capital to $425m and was led by new investors, including Janus Henderson Investors and Eckuity Capital. Existing investors such as T Rowe Price Investment Management and Durable Capital Partners also participated.
The funding will accelerate regulatory approval, manufacturing expansion, and the buildup of a clinical and commercial team, positioning Kardium to compete in the rapidly growing PFA market.
CEO Kevin Chaplin
Field Medical raises $35m Series B to support pulsed field ablation tech
Field Medical has raised $35 million in a Series B round to support a pivotal trial of its FieldForce pulsed field ablation system. BioStar Capital and Cue Growth led the round, which had participation from existing strategic investors, too.
This funding adds to a $40 million Series A brought in earlier this year and brings the Cardiff-by-the-Sea, California-based company’s total funding to $75 million to date. The company expects its Series B to support the initiation of a pivotal trial as it advances the FieldForce ablation system.
CEO and founder Dr. Steven Mickelsen
Escala raises €4.5m for pelvic organ prolapse repair device
Escala Medical has been awarded €4.5 million ($5.3m) to drive market expansion of its Mendit device for women with pelvic organ prolapse.
Around €2.5 million ($2.9m) of the funds for the Israeli femtech company were awarded by the European Innovation Council (EIC), with the remainder coming from a mix of undisclosed US and Israeli investors.
CEO Dr. Edit Goldberg
CroíValve picks up $14.7m from European accelerator
CroíValve has secured approximately $14.7 million in funding from the European Innovation Council (EIC) Accelerator Program to advance its Duo transcatheter tricuspid valve system, designed to treat severe tricuspid regurgitation (TR).
The funding will support further clinical validation of the minimally invasive device, which aims to address a critical gap in care for patients unsuitable for existing first-generation TR treatments.
CEO Lucy O’Keeffe
OutSee raises £1.8m seed funding to expand therapeutic pipeline using AI
OutSee, a genomics and drug discovery company, has raised £1.8 million in seed funding to advance its AI-powered Nomaly technology, which predicts disease and phenotype directly from a single genome without relying on known genetic associations.
The funding – led by Ahren Innovation Capital – will support the expansion of OutSee’s in-house target discovery program and strategic partnerships, with initial applications focused on CNS, rare, and metabolic diseases.
CEO and founder Dr. Julian Gough
Liquet Medical Closes Seed Funding Round
Liquet Medical, a clinical-stage medical device company, raised an undisclosed amount in Seed funding, which officially closed in May 2025. The funds will support its upcoming pilot study, aimed at evaluating real-time hemodynamic response during localized drug delivery in patients with blood clots in the lungs.
Its lead product, the Versus Catheter, has received FDA 510(k) clearance for the controlled infusion of fluids, including thrombolytics, into the pulmonary arteries and for hemodynamic monitoring.
CEO John Schindler
